Skip to main content
. 2021 Jul 16;29(9):2707–2722. doi: 10.1016/j.ymthe.2021.07.001

Figure 6.

Figure 6

The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by CCRF-CEM

(A) Average radiance quantification of each treatment group measured at the indicated time points. The results are displayed as mean ± SEM (n = 5). ∗p < 0.05 and ∗∗∗∗p < 0.0001 (two-way ANOVA). (B) Relative frequency of CD5KO anti-CD5 CAR-T cells (CD45+ EGFR+) in peripheral blood of mice on days 10 and 17 is shown, respectively (n = 3). ∗∗p < 0.01 (two-way ANOVA). (C) Overall Kaplan-Meier survival curve is shown. Survival curves were compared using the log rank test. Mice treated with CAR-T cells showed significantly increased survival (∗∗∗∗p < 0.0001) compared with those of CD5KO-T and PBS-treated groups. (D) Growth and staging of the tumor monitored by bioluminescence imaging are shown. (E) Body weight curve is shown. The results are displayed as mean ± SEM (n = 5). (F) Concentration of IFN-γ and IL-10 in the serum of indicated groups collected on day 17 is shown. The results are displayed as mean ± SD (n = 5). ∗p < 0.05 and ∗∗∗∗p < 0.0001 (one-way ANOVA). (G) Representative flow cytometry analysis shows the proportion of LAG-3+ and TIM-3+ cells in CAR-T cells in the peripheral blood of NCG mice collected on day 24. (H) Quantification and statistical analysis of the results in (G) are shown. The results are displayed as mean ± SD (n = 3). ∗p < 0.05 and ∗∗p < 0.01 (two-way ANOVA).